Federation Des Caisses Desjardins Du Quebec Protalix Bio Therapeutics, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $17.5 Billion
- Q2 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 250 shares of PLX stock, worth $270. This represents 0.0% of its overall portfolio holdings.
Number of Shares
250
Previous 250
-0.0%
Holding current value
$270
Previous $315,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding PLX
# of Institutions
70Shares Held
5.61MCall Options Held
103KPut Options Held
4.6K-
Israel Englander Millennium Management LLC | New York, Ny811KShares$876,0520.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny805KShares$868,9680.0% of portfolio
-
Goldman Sachs Group Inc New York, NY462KShares$498,9140.0% of portfolio
-
Northern Trust Corp Chicago, IL423KShares$457,0700.0% of portfolio
-
Gsa Capital Partners LLP London, X0401KShares$433,3430.03% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $53.7M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...